RYRobert H Yolken

Robert H Yolken

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Robert H Yolken has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Andrea E Origoni

    Stanley Research Center, Sheppard Pratt Health System

    1 shared publication
  • Bogdana Krivogorsky

    Stanley Neurovirology Laboratory, Johns Hopkins School of Medicine, Baltimore, MD, USA

    1 shared publication
  • Cassie Stallings

    Stanley Research Center, Sheppard Pratt Health System

    1 shared publication
  • Faith B Dickerson

    Stanley Research Center, Sheppard Pratt Health System, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA

    1 shared publication
  • Flora Leister

    Stanley Neurovirology Laboratory, Johns Hopkins School of Medicine, Baltimore, MD, USA

    1 shared publication
  • John J Boronow

    Stanley Research Center, Sheppard Pratt Health System

    1 shared publication

Latest Publications

  • The catechol O ‐methyltransferase Val158Met polymorphism and herpes simplex virus type 1 infection are risk factors for cognitive impairment in bipolar disorder: additive gene‐environmental effects in a complex human psychiatric disorder

    by Faith B Dickerson, John J Boronow, Cassie Stallings, Andrea E Origoni, Sara Cole, Flora Leister, Bogdana Krivogorsky, Robert H Yolken

    Background:  Bipolar disorder is associated with deficits in cognitive functioning. The etiology of cognitive impairment in bipolar disorder may relate to both genetic and environmental factors. A valine/methionine polymorphism of the catechol O ‐methyltransferase gene at amino acid 158 (COMT Val158Met polymorphism) has been identified as a risk factor for cognitive impairment in schizophrenia. Serological evidence of infection with herpes simplex virus type 1 (HSV‐1) has also been identified as a risk factor for cognitive impairment in bipolar disorder. Methods:  We used Taqman technology to measure COMT Val158Met alleles in 107 individuals with bipolar disorder and in 95 controls. We also measured antibodies to HSV‐1 in sera obtained from the same individuals. Cognitive functioning was assessed with the Repeatable Battery for the Assessment of Neuropsychological Status and the Letter‐Number Sequencing Test. The effects of the COMT Val158Met polymorphism and antibodies to HSV‐1 on cognitive functioning were analyzed with multinomial logistic regressions. Results:  The COMT Val158Val genotype and serological evidence of infection with HSV‐1 are independent risk factors for cognitive impairment in individuals with bipolar disorder, particularly in the domains of immediate and delayed memory. Individuals with bipolar disorder with the COMT158 Val/Val genotype and serological evidence of HSV‐1 infection were more than 85 times more likely to be in the lowest quintile of cognitive functioning when compared with the highest quintile when controlling for potential confounding variables such as symptom severity and education. Control individuals did not display this association. Conclusion:  Both the COMT Val158Met polymorphism and serological evidence of HSV‐1 infection affect cognitive functioning in individuals with bipolar disorder.